Home / Market News / $CRBP
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

HC Wainwright & Co. Raises Crescent Biopharma Price Target to $40

Nov 14, 2026, 2:06 PM UTC · Primary ticker $CRBP

HC Wainwright & Co. increased its price target for Crescent Biopharma from $36 to $40 per share. This analyst upgrade signals a more optimistic outlook on the company's future valuation, potentially leading to positive short-term investor sentiment.

HC Wainwright & Co. announced an increase in its price target for Crescent Biopharma, Inc. to $40.00 per share from $36.00. This analyst upgrade reflects a more favorable view of the company's prospects, likely based on recent developments or updated financial models. For traders, this could generate positive short-term momentum for Crescent Biopharma's stock as it signals increased confidence from a research firm. While not a fundamental change in the company's operations, analyst upgrades can influence investor perception and trading activity, creating a potential opportunity for those looking to capitalize on positive sentiment.

$CRBP positive Analyst price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.